Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,878.41 +1.36 (+0.02%) Bitcoin USD
64,663.90 +854.34 (+1.34%) CMC Crypto 200
1,369.01 +56.38 (+4.49%)
Shockwave Medical, Inc. (SWAV)
| Previous close | 327.52 |
| Open | 327.58 |
| Bid | 301.59 x 200 |
| Ask | 354.17 x 200 |
| Day's range | 327.39 - 328.38 |
| 52-week range | 157.00 - 331.58 |
| Volume | |
| Avg. volume | 1,033,695 |
| Market cap | 12.303B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 84.97 |
| EPS (TTM) | 3.86 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 316.14 |
BenzingaJohnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue
ZacksWhy Shockwave Medical (SWAV) Could Beat Earnings Estimates Again
Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ZacksPharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
